Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: The TEEN/TWEN study

Haemophilia

Volumn 19, Issue 5, 2013, Pages 727-735

  Manco Johnson, M J ^a   Sanders, J ^b   Ewing, N ^c   Rodriguez, N ^d   Tarantino, M ^e   Humphries, T ^f  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b Cook Children's Medical Center ^*  (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Bleeding and Clotting Disorders Institute   (United States)

^f BAYER CORPORATION   (United States)

Author keywords

Adolescents; Factor VIII therapy; Haemophilia; On demand therapy; Prophylaxis; Quality of life; Switching

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GILBERT SCORE; GODIN LEISURE TIME QUESTIONNAIRE; HAEMO QOL A HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE; HAEMOPHILIA ACTIVITIES LIST; HEMARTHROSIS; HEMOPHILIA A; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATE TRAIT ANXIETY INVENTORY;

ADOLESCENTS; FACTOR VIII THERAPY; HAEMOPHILIA; ON-DEMAND THERAPY; PROPHYLAXIS; QUALITY OF LIFE; SWITCHING;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FACTOR IX; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883053954     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12177     Document Type: Article

References (34)

1. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004; 10: 97-104.
2. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document #179. Available at: http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf. Accessed August 28, 2012.
3. Delivery of Treatment for Hemophilia. Report of a Joint WHO/WFH/ISTH Meeting. London, UK. Available at: http://libdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf. Accessed August 28, 2012.
4. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9: 1-4.
5. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; Suppl 77: 3-132.
6. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
8. Khoriaty R, Taher A, Inati A, Lee C. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol 2005; 27: 320-3.
9. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
10. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
11. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
12. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
13. Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18: 568-74.
14. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia 2006; 12: 75-81.
15. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16: 181-8.
16. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13(Suppl 2): 16-22.
17. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
18. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
19. Pollak E, Muhlan H, Von Mackensen S, Bullinger M. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 2006; 12: 384-92.
20. Rentz A, Flood E, Altisent C et al. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14: 1023-34.
21. van Genderen FR, Westers P, Heijnen L et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12: 36-46.
22. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985; 10: 141-6.
23. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1983.
24. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
25. Gringeri A, Leissinger C, Cortesi P, Matovani LG. Bleeding prophylaxis with an anti-inhibitor coagulant complex (AICC) in patients with hemophilia A and inhibitors can improve quality of life: results of the PRO-FEIBA study. Presented at: XXIII Congress of the International Society on Thrombosis and Haemostasis, July 23-28, 2011; Kyoto, Japan.
26. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
27. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 2005; 7: 1-39.
28. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11: 92-9.
29. Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008; 119: 115-23.
30. Biss TT, Chan AK, Blanchette VS et al. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
31. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18: 63-8.
32. De Moerloose P, Fischer K, Lambert T et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18: 319-25.
33. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47.
34. World Health Organization. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular Risk. Geneva, Switzerland: WHO Press, 2007.